Emergent Biosolutions Inc (NYSE:EBS) Director Sue Bailey sold 8,375 shares of Emergent Biosolutions stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $53.46, for a total transaction of $447,727.50. Following the completion of the transaction, the director now owns 46,333 shares in the company, valued at $2,476,962.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

EBS stock traded down $1.79 during trading on Friday, reaching $52.24. 13,079 shares of the company were exchanged, compared to its average volume of 301,345. The company has a market cap of $2.75 billion, a P/E ratio of 22.42, a PEG ratio of 0.87 and a beta of 1.50. Emergent Biosolutions Inc has a 52-week low of $39.11 and a 52-week high of $67.45. The stock’s 50 day moving average price is $54.92 and its 200 day moving average price is $49.01. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.71 and a current ratio of 2.54.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.21 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.58. The firm had revenue of $311.80 million for the quarter, compared to the consensus estimate of $289.16 million. Emergent Biosolutions had a net margin of 0.42% and a return on equity of 10.05%. The firm’s revenue was up 79.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.55 earnings per share. As a group, equities research analysts forecast that Emergent Biosolutions Inc will post 3.08 EPS for the current year.

A number of research analysts have commented on the stock. Laidlaw set a $72.00 price objective on shares of Emergent Biosolutions and gave the company a “buy” rating in a research note on Wednesday, September 4th. TheStreet raised shares of Emergent Biosolutions from a “c” rating to a “b” rating in a report on Wednesday, November 6th. Chardan Capital reaffirmed a “buy” rating and issued a $71.00 target price on shares of Emergent Biosolutions in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $75.00 target price on shares of Emergent Biosolutions in a report on Friday, November 22nd. Finally, Cowen reaffirmed a “hold” rating and issued a $67.00 target price on shares of Emergent Biosolutions in a report on Monday, November 25th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $69.00.

A number of hedge funds have recently added to or reduced their stakes in the stock. Earnest Partners LLC raised its stake in Emergent Biosolutions by 860.6% in the 2nd quarter. Earnest Partners LLC now owns 1,692,171 shares of the biopharmaceutical company’s stock valued at $81,749,000 after acquiring an additional 1,516,013 shares during the period. Millennium Management LLC acquired a new stake in shares of Emergent Biosolutions during the 3rd quarter worth $19,579,000. Jennison Associates LLC grew its holdings in shares of Emergent Biosolutions by 197.0% during the 2nd quarter. Jennison Associates LLC now owns 562,121 shares of the biopharmaceutical company’s stock worth $27,156,000 after purchasing an additional 372,857 shares in the last quarter. Tygh Capital Management Inc. grew its holdings in shares of Emergent Biosolutions by 211.1% during the 3rd quarter. Tygh Capital Management Inc. now owns 298,488 shares of the biopharmaceutical company’s stock worth $15,605,000 after purchasing an additional 202,527 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Emergent Biosolutions by 119.5% during the 2nd quarter. Wells Fargo & Company MN now owns 344,191 shares of the biopharmaceutical company’s stock worth $16,628,000 after purchasing an additional 187,359 shares in the last quarter. 86.61% of the stock is currently owned by hedge funds and other institutional investors.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Further Reading: How can investors invest in the Euro STOXX 50 Index?

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.